Academic Journals Database
Disseminating quality controlled scientific knowledge

Lenalidomide in Patients with Multiple Myeloma who have Received One Prior Therapy

ADD TO MY LIST
 
Author(s): Monique Hartley | Rachid Baz

Journal: The Asia-Pacific Journal of Oncology & Hematology
ISSN 1759-6637

Volume: 2;
Issue: 1;
Start page: 23;
Date: 2010;
VIEW PDF   PDF DOWNLOAD PDF   Download PDF Original page

Keywords: multiple myeloma | novel therapies | lenalidomide

ABSTRACT
Lenalidomide, an IMiD® immunomodulatory drug, has been shown to enhance NK and T-cell function as well as to result in direct tumoricidal effects on multiple myeloma (MM) cell lines. Lenalidomide is more potent yet has differential toxicities than the parent compound thalidomide. Two pivotal studies by Weber, et al, and Dimopoulos, et al, have demonstrated clinically significant long-term benefits in patients with relapsed/refractory MM, including overall response rate, progression-free survival, and survival of the combination of lenalidomide and dexamethasone compared with dexamethasone alone. In addition, lenalidomide has been extensively evaluated in combination with other agents and in the newly diagnosed setting for MM with demonstrable activity. In this paper, we review the preclinical and clinical data underlying its use in patients with MM.
RPA Switzerland

Robotic Process Automation Switzerland

    

Tango Rapperswil
Tango Rapperswil